Tenderwize
Wróć do wyszukiwania

Open-house discount agreement for Sorafenib

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sorafenib, ATC L01EX02

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so the us...

Submission requires either handwritten originals in duplicate or a qualified electronic signature via DTVP; incorrect f...

Submission deadline in 8 days

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive open-house discount agreements for the medicinal product Sorafenib, ATC L01EX02.
  • Supply-related pharmaceutical contract under German social law framework stated by the buyer.
Pokaż pełne podsumowanie

This is an open-house supply arrangement for pharmaceutical discount agreements on Sorafenib (ATC L01EX02) by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated eligibility condition can join on identical, non-negotiable terms. The contract period runs from 01.11.2024 to 31.10.2026, with contract entry possible until 05.09.2026. Submission can be by handwritten paper originals or by qualified electronic signature via DTVP. No contract value is stated.

Ryzyka

The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so the us...

Submission requires either handwritten originals in duplicate or a qualified electronic signature via DTVP; incorrect f...

Submission deadline in 8 days

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house discount agreement for Sorafenib

Single lot for non-exclusive open-house pharmaceutical discount agreements concerning Sorafenib (ATC L01EX02). The buyer states that identical, non-individually negotiable contracts are offered to all interested pharmaceutical companies meeting the eligibility condition. Performance is in Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Oct 2024 - Oct 2026

Kategoria

Pharmaceutical products

Termin

Deadline Sep 05, 2026

Szczegóły zamówienia

Data publikacji
16 Sep 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
557828-2024

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30